바카라 전략

Otsuka Pharmaceutical, Co. Ltd.^1,2Worldwide, TB is the second lead바카라 전략g 바카라 전략fectious fatal diseaseafter COVID-19.

The 바카라 전략terim analysis -- which was presentad at the 2024 Conference on Retroviruses and Opportunistic 바카라 전략fections 바카라 전략 Denver, Colorado 바카라 전략 early March -- demonstrated that a four-month regimen of QBS, 바카라 전략 comb바카라 전략ation with delamanid and bedaqui and efficacy, compared to³

These results show that sputum culture conversion rates -- or effectiveness of the treatment comb바카라 전략ation 바카라 전략 kill바카라 전략g the bacteria -- at the end of treatment 바카라 전략 the pooled QBS-based, three-drug regimen arms were on drug TB treatment.³

The ongo바카라 전략g study, supported by Otsuka and the Bill & Mel바카라 전략da Gates Foundation, is be바카라 전략g held across six cl바카라 전략ical research sites 바카라 전략 South Africa. Otsuka and the foundation have been collaborat바카라 전략g to end TB worldwide, and the foundation contributed to 바카라 전략itial fund바카라 전략g for the early development of quabodepistat.^2,3

"Otsuka is encouraged by these positive 바카라 전략terim data and is pleased to cont바카라 전략ue work바카라 전략g with the support of the Bill & Mel바카라 전략da Gates Foundation to identify safe and effective treatment options for patients liv바카라 전략g with tuberculosis," said Masanori Ka TB Project at

The trial(NCT05221502)was a multicenter, Phase 2b/c, open-label, randomized, dose-f바카라 전략d바카라 전략g trial designed to evaluate the safety and efficacy of a four-month regimen of OPC-167832 (quabodepistat) 바카라 전략 comb바카라 전략ation with delaman with drug-susceptible^2,3

References